Wall Street analysts expect Collegium Pharmaceutical Inc (NASDAQ:COLL) to report earnings of ($0.11) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Collegium Pharmaceutical’s earnings, with the lowest EPS estimate coming in at ($0.15) and the highest estimate coming in at ($0.06). Collegium Pharmaceutical reported earnings of ($0.45) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 75.6%. The firm is expected to issue its next quarterly earnings report after the market closes on Thursday, November 8th.
According to Zacks, analysts expect that Collegium Pharmaceutical will report full-year earnings of ($0.63) per share for the current year, with EPS estimates ranging from ($0.72) to ($0.49). For the next fiscal year, analysts expect that the firm will report earnings of $0.60 per share, with EPS estimates ranging from $0.00 to $1.20. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.02. Collegium Pharmaceutical had a negative net margin of 39.10% and a negative return on equity of 61.82%. The company had revenue of $73.10 million for the quarter, compared to analyst estimates of $72.21 million. The business’s quarterly revenue was up 1930.6% on a year-over-year basis.
A number of research firms have recently commented on COLL. Cantor Fitzgerald set a $35.00 price target on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Friday, September 21st. ValuEngine lowered shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Tuesday, July 10th. Zacks Investment Research lowered shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday. BidaskClub lowered shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, July 10th. Finally, Janney Montgomery Scott set a $27.00 price target on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Monday, August 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $31.71.
In other news, Director Michael Thomas Heffernan sold 25,000 shares of the firm’s stock in a transaction on Monday, October 15th. The shares were sold at an average price of $16.53, for a total value of $413,250.00. Following the sale, the director now owns 361,000 shares in the company, valued at $5,967,330. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 13.87% of the company’s stock.
Several institutional investors have recently made changes to their positions in COLL. Millennium Management LLC grew its stake in shares of Collegium Pharmaceutical by 1,171.8% in the second quarter. Millennium Management LLC now owns 361,035 shares of the specialty pharmaceutical company’s stock worth $8,611,000 after acquiring an additional 332,647 shares during the last quarter. Summit Trail Advisors LLC boosted its stake in Collegium Pharmaceutical by 2,221.9% during the first quarter. Summit Trail Advisors LLC now owns 332,708 shares of the specialty pharmaceutical company’s stock worth $333,000 after buying an additional 318,379 shares in the last quarter. BlackRock Inc. boosted its stake in Collegium Pharmaceutical by 13.8% during the second quarter. BlackRock Inc. now owns 2,252,273 shares of the specialty pharmaceutical company’s stock worth $53,717,000 after buying an additional 272,302 shares in the last quarter. Macquarie Group Ltd. boosted its stake in Collegium Pharmaceutical by 9.9% during the second quarter. Macquarie Group Ltd. now owns 2,588,356 shares of the specialty pharmaceutical company’s stock worth $61,732,000 after buying an additional 233,598 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in Collegium Pharmaceutical by 78.5% during the second quarter. Northern Trust Corp now owns 526,499 shares of the specialty pharmaceutical company’s stock worth $12,557,000 after buying an additional 231,463 shares in the last quarter. Institutional investors and hedge funds own 93.76% of the company’s stock.
Shares of NASDAQ:COLL traded up $0.46 during trading on Tuesday, reaching $16.95. The stock had a trading volume of 556,723 shares, compared to its average volume of 522,759. Collegium Pharmaceutical has a 52 week low of $9.01 and a 52 week high of $29.90. The firm has a market cap of $544.84 million, a price-to-earnings ratio of -6.86 and a beta of 0.43. The company has a quick ratio of 0.78, a current ratio of 0.82 and a debt-to-equity ratio of 3.94.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Recommended Story: Call Option
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.